BioGaia’s result for first quarter to exceed market expectations

(Figures in brackets refer to the same period the previous year)

BioGaia´s sales for the first quarter has been positively impacted by an increased demand mainly from the European market.

Sales for the first quarter are preliminarily estimated at SEK 284 million (202), up 41%. Operating profit for the first quarter is preliminarily estimated at SEK 95 million (64), up 48%.

BioGaia will publish the interim report for the first quarter on Friday, 6 May 2022 at 8:00 a.m., followed by a teleconference at 9:30 a.m.

Latest press releases from BioGaia:

05.04.2022 Notice to attend the Annual General Meeting of BioGaia AB (publ)
28.03.2022 BioGaia publishes annual report for 2021
04.02.2022 BioGaia AB – Year-end Report 2021
 

This disclosure contains information that BioGaia is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 25-04-2022 08:00 CET.

For additional information please contact
Isabelle Ducellier, CEO: +46 8 555 293 00

BioGaia is an innovative Swedish healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are sold through local distribution partners in more than 100 countries worldwide. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. biogaia.com